Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Congressional Budget Office, which suggested the cost of the drugs could still exceed the savings from treating obesity and its attendant health conditions
Save hot meals for periods when symptoms allow
Wegovy (semaglutide) is a once-a-week injection thats approved by the Food and Drug Administration (FDA) to: Reduce excess body weight and maintain weight reduction in: Adults with a body mass index (BMI) of 30 or higher Adults with a BMI of 27 or higher who also have weight-related medical problems, such as high cholesterol or high blood pressure Adolescents ages 1217 who are at or above the 95th percentile on sex- and age-specific growth charts Reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and a BMI of 27 or higher Wegovy belongs to a family of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists)
The true cost over six months could be significantly higher than initial expectations suggest
Molecular Characteristics Retatrutide is a single sequence-engineered peptide designed to combine agonist activity at GIPR, GLP-1R and GCGR within one modified molecular structure
